Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors-Reference-Cited by-同舟云学术

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

Published:2018-09-20 Issue:1 Volume:98 Page:159-167
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Stein Anthony S.,Schiller Gary,Benjamin Ramsis,Jia Catherine,Zhang Alicia,Zhu Min,Zimmerman Zachary,Topp Max S.

Funder

Amgen Inc.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-018-3497-0/fulltext.html

Reference21 articles.

1. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, AK MM, Tallman MS, Rowe JM, Goldstone AH, Medical Research Council of the United Kingdom Adult ALLWP, Eastern Cooperative Oncology G (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3):944–950. https://doi.org/10.1182/blood-2006-05-018192

2. Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D, German Multicenter Study Group for Adult Acute Lymphoblastic L (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120(10):2032–2041. https://doi.org/10.1182/blood-2011-12-399287

3. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186–3191. https://doi.org/10.1002/cncr.23919

4. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974–977. https://doi.org/10.1126/science.1158545

5. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57–66. https://doi.org/10.1016/S1470-2045(14)71170-2

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

2. A Pediatric Case of B Cell Precursor ALL With Blinatumomab-associated Encephalopathy;Journal of Pediatric Hematology/Oncology;2024-07-15

3. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy;Acta Pharmaceutica Sinica B;2024-06

4. Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus;Viruses;2024-05-29

5. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer;Cancer Biology & Therapy;2024-05-27